Genzyme Fabrazyme/Transkaryotic Replagal to committee
This article was originally published in Pharmaceutical Approvals Monthly
FDA's Endocrinologic & Metabolic Drugs Advisory Committee will consider competing Fabry disease therapies at its September meeting; Genzyme's Fabrazyme (agalsidase beta) will be reviewed Sept. 26, followed by Transkaryotic Therapies' Replagal (agalsidase alfa) Sept. 27. Presumably, the first-approved drug would gain seven years orphan drug exclusivity and block the other's approval. The agents are approved with co-exclusive orphan status in Europe, but FDA has never awarded simultaneous orphan exclusivit
You may also be interested in...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.
NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.